Medications in smoking cessation;Médicaments d'aide au sevrage tabagique

Presse Medicale

Volumn 34, Issue 18, 2005, Pages 1331-1336

  Mansourati, Jacques ^a,b   Borel, M L ^a   Munier, S ^a   Guevel Jointret, A L ^a  

^a CHU de Brest 29   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; NICOPATCH; NICOTINE DERIVATIVE; NICOTINE GUM; NICOTINEL TTS; NIQUITIN; NIQUITIN CLEAR; UNCLASSIFIED DRUG;

BEHAVIOR; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG RELEASE; HEART DISEASE; HUMAN; MOUTH MUCOSA; PHYSICIAN; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT FAILURE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 27544451199     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84182-x     Document Type: Review

References (20)

1. Euroaspire I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
2. Le Houezec J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int J Tuberc Lung Dis 2003; 7: 811-19.
3. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196-203.
4. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281: 72-6.
5. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A metaanalysis. JAMA 1994; 271: 1940-7.
6. Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ 1994; 308: 21-6.
7. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Presse Med 1995; 24: 41-7.
8. Lefoll B, Aubin HJ, Lagrue G. Les thérapies comportementales et cognitives dans l'aide à l'arrêt du tabac. Ann Med Int 2002; 153: 1S32-1S40.
9. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119-27.
10. Benowitz NL, Porchet H, Scheiner L, Jacob P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44: 23-8.
11. Agence française de sécurité sanitaire des produits de santé. Les stratégies thérapeutiques médicamenteuses et non médicamenteuses de l'aide à l'arrêt du tabac. Recommandations. Mai 2003.
12. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
13. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321-7.
14. Lebargy F. La dépendance nicotinique. Rev Pneumol Clin 2000; 56: 177-83.
15. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-202.
16. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24: 946-55.
17. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-91.
18. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59: 366-73.
19. Anthenelli RM, Depres J-P. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (smoking cessation in smokers motivated to quit) and the RIO-LIPIDS Trial (weight reducing and metabolic effects in overweight/obese patients with dyslipidemia). American College of Cardiology, Annual Scientific Session, March 9, 2004.
20. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.